|June 30, 2014|
|16:41 EDT||CG, JNJ||Johnson & Johnson completes divestiture of unit to Carlyle Group |
Johnson & Johnson (JNJ) announced that it has completed the divestiture of its Ortho-Clinical Diagnostics business to The Carlyle Group (CG) for approximately $4B, subject to customary adjustments. Under the terms of the transaction, The Carlyle Group has acquired the Ortho-Clinical Diagnostics business, a global provider of solutions for screening, diagnosing, monitoring and confirming diseases. The Ortho-Clinical Diagnostics business generated net sales of approximately $1.9B in 2013.
News For JNJ;CG From The Last 14 Days
|July 1, 2015|
|18:59 EDT||CG||Carlyle Group in talks for 37% stake in Metropolis Health, Times of India says|
Carlyle Group is in advanced discussions to purchase a 37% stake in Metropolis Healthcare for RS900 crore, reports Times of India, citing people directly familiar with the matter. Sources said a deal could be reached within the next few weeks. Reference Link
|16:33 EDT||JNJ||Gilead submits NDA to FDA for single tablet regimen for HIV containing R/F/TAF |
Gilead Sciences (GILD) announced that it has submitted a New Drug Application, or NDA, to the FDA for an investigational, once-daily single tablet regimen that combines Gileadís emtricitabine 200 mg and tenofovir alafenamide, or TAF, 25 mg with rilpivirine 25 mg, or R/F/TAF, from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), for the treatment of HIV-1 infection in adult and pediatric patients 12 years of age and older. The data submitted in the NDA support the use of R/F/TAF among patients who are HIV treatment-naÔve or who are virologically suppressed and want to replace their current antiretroviral treatment regimen. A Priority Review voucher acquired from Knight Therapeutics in November 2014 was submitted to the FDA along with the R/F/TAF NDA. Under the Prescription Drug User Fee Act, or PDUFA, the anticipated target action date for the R/F/TAF NDA is six months after the FDAís acceptance of the filing. TAF is a novel, investigational nucleotide reverse transcriptase inhibitor, or NRTI, that has demonstrated high antiviral efficacy at a dose less than one-tenth that of Gileadís Viread, as well as improved renal and bone laboratory parameters as compared to TDF in clinical trials in combination with other antiretroviral agents. In addition to R/F/TAF, two other TAF-based HIV treatments are also under FDA review.
|June 29, 2015|
|06:07 EDT||CG||BMW, Macquarie expected to bid for ANZ Banking unit, Reuters reports|
According to a source familiar of the situation, BMW and Macquarie Group are among the companies expected to make a bid for Australia and New Zealand Banking Group's car and equipment loan book, Reuters reports. Additionally, buyout firms Carlyle (CG), Blackstone (BX) and TPG have requested information memorandums for the sale. The unit could fetch more than the $6.35B book value of the loans, the source says. Reference Link
|June 28, 2015|
|17:44 EDT||CG||Carlyle Group to invest $120M in Shanghai ANE Logistics|
The Carlyle Group announced that it has agreed to invest approximately $120M into Shanghai ANE Logistics. The transaction is expected to close in Q3. Equity for the transaction will come from Carlyle Asia Partners IV.
|June 22, 2015|
|07:55 EDT||CG||Sotherly Hotels agrees to acquire remaining interest in Crowne Plaza Hollywood|
Subscribe for More Information
|June 21, 2015|
|19:55 EDT||CG||Carlyle Group commits up to $500M to Magna Energy|
The Carlyle Group announced that it is committing an equity line up to $500M in Magna Energy, an upstream oil and gas company. Magna is targeting the building of acreage positions in the Indian subcontinent, with the objective of creating a full-cycle oil and gas company through acquisitions and local licensing rounds. Magnaís primary focus will be development and production with a secondary focus on exploration, said Carlyle.